Antitumor action of lymphokin-activated cells of patients with soft tissue sarcomas and melanomas in dependence on expression of MHC classes I and II antigenes.
OBJECTIVE
To study expression of major histocompatibility complex (MHC) classes and antigens and CD25, CD71, Ki-67, CD54, CD56, CD11b, PCNA on lymphocytes and tumor cells and antitumor action of lymphocytes activated with IL-2.


METHODS
Tumor explants (soft tissue sarcoma, n = 20, melanoma, n = 25) were co-cultivated in diffusion chambers with autologous lymphocytes; antitumor action was evaluated by morphologic patterns of explant's growth. Expression of CD25, CD71, Ki-67, CD54, CD56, CD11b, PCNA was evaluated by the method of indirect fluorescence using respective monoclonal antibodies.


RESULTS
The highest antitumor action of lymphocytes toward soft tissue sarcoma and melanoma cells is observed if tumor cells are expressing MHC class I antigens. In the cases of soft tissue sarcoma no correlation between the level of antitumor activity of lymphocytes and expression of CD25, CD71, Ki-67, CD54, CD56, CD11b, PCNA has been found, whilst in the case of melanoma it is associated with the high level of CD11b expression.


CONCLUSIONS
There is a direct correlation between sensitivity of soft tissue sarcoma and melanoma cells to action of lymphokin-activated killer cells and the level of MHC class I antigens.
Berezhnaya
N M
NM
R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv 03022, Ukraine. berezh@onconet.kiev.ua
Vinnichuk
U D
UD
Belova
O B
OB
Baranovich
V V
VV
D015703:Antigens, CD / Q000032:analysis; D018920:Coculture Techniques; D003602:Cytotoxicity, Immunologic; D015395:Histocompatibility Antigens Class I / Q000032:analysis / Q000378:metabolism*; D000949:Histocompatibility Antigens Class II / Q000032:analysis / Q000378:metabolism*; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D019394:Ki-67 Antigen / Q000032:analysis; D007694:Killer Cells, Natural / Q000737:chemistry / Q000187:drug effects / Q000276:immunology; D008213:Lymphocyte Activation; D008222:Lymphokines / Q000494:pharmacology; D008545:Melanoma / Q000276:immunology*; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D012509:Sarcoma / Q000276:immunology*; D012878:Skin Neoplasms / Q000276:immunology*
D015703:Antigens, CD; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D007376:Interleukin-2; D019394:Ki-67 Antigen; D008222:Lymphokines; D018809:Proliferating Cell Nuclear Antigen